Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, April 30, 2015 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class modulator of the brain's innate immune system, as a potential treatment for...
-
NEW YORK, Jan. 7, 2015 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class modulator of the brain's innate immune system, as a potential treatment for...
-
NEW YORK, Sept. 30, 2014 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class microglial modulator, as a potential treatment for Alzheimer's disease (AD),...
-
NEW YORK, Feb. 21, 2014 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing the first-in-class microglial modulator CHF 5074 as a potential treatment for Alzheimer's disease (AD),...
-
NEW YORK, Jan. 10, 2014 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator as a potential treatment for Alzheimer's disease, today...
-
NEW YORK, Nov. 26, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator, as a potential treatment for Alzheimer's disease,...
-
NEW YORK and PARMA, Italy, Nov. 8, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated and Chiesi Farmaceutici S.p.A. today announced CereSpir has acquired the worldwide development and...
-
Patients with Mild Cognitive Impairment treated with CHF 5074 for up to 90 weeks demonstrated highly statistically significant improvements in verbal memory and executive...
-
CHF 5074 is a novel, first-in-class small molecule microglia modulator created by Chiesi Final results of a 14-week, double-blind, placebo-controlled Phase 2 study in 96 MCI patients and...